It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
The combined phenotype of thrombocytopenia accompanied by intellectual disability in patients with a de novo heterozygous mutation, i.e., p.Tyr64Cys in CDC42, signifies a clinically recognizable novel syndrome that has been eponymized as “Takenouchi-Kosaki syndrome” (OMIM #616737). In the present study, a detailed phenotypic analysis performed for a total of five patients with Takenouchi-Kosaki syndrome revealed that intellectual disability, macrothrombocytopenia, camptodactyly, structural brain abnormalities with sensorineural deafness, hypothyroidism, and frequent infections comprise the cardinal features of this condition. A morphologic analysis of platelets derived from three affected individuals was performed using electron microscopy. The platelets of the three patients were large and spherical in shape. Furthermore, platelet α-granules were decreased, while vacuoles were increased. We further performed a functional analysis of p.Tyr64Cys in CDC42 through CRISPR/Cas9-mediated gene editing in a Caenorhabditis elegans model. This functional analysis suggested that the mutant allele has hypomorphic effects. Takenouchi-Kosaki syndrome is clinically recognizable by the combined phenotype of intellectual disability, macrothrombocytopenia, camptodactyly, structural brain abnormalities with sensorineural deafness, hypothyroidism, and frequent infections as well as the identification of a heterozygous de novo mutation in CDC42, i.e., p.Tyr64Cys.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details


1 Keio University School of Medicine, Center for Medical Genetics, Tokyo, Japan (GRID:grid.26091.3c) (ISNI:0000 0004 1936 9959)
2 Graduate School of Medicine, Nippon Medical School, Division of Morphological and Biomolecular Research, Tokyo, Japan (GRID:grid.410821.e) (ISNI:0000 0001 2173 8328)
3 Osaka Women’s and Children’s Hospital, Department of Medical Genetics, Osaka, Japan (GRID:grid.410821.e)
4 Misakaenosono Mutsumi Developmental, Medical, and Welfare Center, Isahaya, Japan (GRID:grid.410821.e)
5 University of Michigan, Division of Pediatric Genetics, Metabolism and Genomic Medicine, Department of Pediatrics, Ann Arbor, USA (GRID:grid.214458.e) (ISNI:0000000086837370)
6 Tokyo Women’s Medical University School of Medicine, Department of Physiology, Tokyo, Japan (GRID:grid.410818.4) (ISNI:0000 0001 0720 6587)
7 Keio University School of Medicine, Department of Pediatrics, Tokyo, Japan (GRID:grid.26091.3c) (ISNI:0000 0004 1936 9959)